logo-loader
viewSynairgen PLC

Synairgen completes recruitment for coronavirus trial

Snapshot

  • Focused on respiratory disease
  • Two drug candidates, one developed in-house, one by a partner
  • Lead candidate tested for coronavirus
lung x-ray

Quick facts: Synairgen PLC

Price: 40.05 GBX

AIM:SNG
Market: AIM
Market Cap: £59.85 m
Follow

Coronavirus

Synairgen plc (LON:SNG) has received approval to test its lead candidate to treat patients with coronavirus.

SNG001 is an inhaled interferon beta drug candidate designed for people with chronic obstructive pulmonary disease (COPD) who are also suffering cold or flu infections.

Earlier studies have shown treatment activated antiviral pathways in the lung along with improving lung function for sufferers with a respiratory viral infection. The drug is also well tolerated.

Synairgen's phase II trial in COVID-19 patients will be a double-blind, placebo-controlled trial, starting with an initial 100 people.

In May, the group said it had completed recruitment of hospitalised patients with coronavirus (COVID-19) for its clinical trial of SNG001.

The 220 patient trial comprises 100 patients initiated in hospitals and 120 patients initiated in the home setting.

LOXL2

The company’s Australian partner has completed phase I trials and toxicology on a LOXL2 inhibitor developed by Synairgen.

This now paves the way for Pharmaxis to advance discussions with potential partners for the drug, which has been developed to treat non-alcoholic liver disease (NASH) and a rare lung condition.

The company retains a 17% “carried interest” in the asset.

 

Synairgen’s BioBank

Over the years, Synairgen has accumulated an extensive bank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or COPD. Using this resource, the company has developed a number of advanced tissue models.

It uses these models to:

  • Discover novel drug targets
  • Identify disease-related lesions and underlying molecular mechanisms
  • Conduct proof of concept testing and validation of novel drug targets
  • Conduct screening assays for novel drug targets and lead target selection
  • Provide support for clinical trial activities

 

What the boss says: Richard Marsden, chief executive

"We have worked intensively with the relevant authorities and collaborators to enable SNG001 to be assessed in COVID-19 patients. SNG001 has been well-tolerated in clinical trials in over 200 respiratory patients to date and has accelerated lung function recovery in two Phase II asthma trials in patients with a cold or flu infection."

“A successful outcome from this trial in COVID-19 patients would be a major breakthrough in the fight against this coronavirus pandemic."

Video

Inflexion points 

  • Results from COVID-19 trial
  • Partner for NASH candidate
  • Raised £14mln in March to fund trials

 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read